» Download Public Reports
About 100 reports
- Company report
- November 2012
- 2 pages
... For the discovery that mature cells can be reprogrammed to become pluripotent Fda gave the green light for duke university to use stem cells found in umbilical cord blood to treat cancer, blood disorders ...
October 2012
... Of moderate to severe stage parkinson S disease that is designed to act on neural stem and progenitor cells in the brain. In animal models of parkinson S disease, treatment with snn0031 restores motor function ...
October 2012
... At osiris as we move rapidly into the commercialization of stem cell medicine," said c. Randal mills, ph.D., President and chief executive officer of osiris. "Over the past six years, lode has proven ...
November 2012
... Celect at its european manufacturing plant in sittard-geleen in the netherlands. The state- of-the-art manufacturing site is unique in europe as it is 100% geared towards the production of innovative cell ...
December 2012
... therapy Ensuring timely delivery of pipeline timely delivery is a core component of our strategy. As one of the leading companies in the field of gene therapy and immunotherapy, we work closely ...
February 2013
... Human stem cells institute ojsc (hsci, www.Hsci.En) is a russian public biotech company founded in 2003. Hsci engages in r&d as well as commercialization and marketing of innovative proprietary products ...
March 2013
... therapies in uk clinical trial and clinical use value investible propositions created leading to cell therapy companies that succeed and stay in the uk attractiveness demonstrating that the uk ...
November 2012
... Actuaries.Org.Uk cells, chemicals (drugs) or biologics cell therapies may function transiently to deliver signals that Stimulate a patients own stem cell-based repair system and/or Exert an anti ...
February 2013
... Of regenerative medicine and cell therapies Support for the development of enabling platform tools and technologies. Proposals to address development issues such as preclinical; formulation and delivery ...
» Purchase Premium Reports
(From $ 250 - $ 750)
25 reports
- $ 750
- Company report
- May 2013
- by Global Data
Summary TiGenix NV (TiGenix) is a biomedical cell therapy company. The company specializes in the development of innovative local treatments for damaged and diseased tissues. It mainly focuses on the therapeutic ...
March 2013
$ 300
Summary Biocompatibles International Ltd. (Biocompatibles) is a medical technology company, engaged in the development of products used for the treatment of cancer and benign tumors. The company is divided ...
March 2013
$ 300
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...
April 2013
$ 250
Summary Chemokine Therapeutics Corp. (Chemokine Therapeutics) is a publicly held biotechnology company. It is engaged in the discovery and develops peptide analogs of chemokines for cancer treatment and ...
April 2013
$ 250
Summary CMC Biologics A/S (CMC Biologics) is a contract biopharmaceutical manufacturing and development organization. It offers manufacturing services of DNA, active pharmaceutical ingredient, and others. ...
April 2013
$ 250
Summary Chip-Man Technologies Ltd. (Chip-Man) is a healthcare technology company, based in Finland. The company conducts research, develops, manufactures and commercializes medical products. It offers ...
April 2013
$ 250
Summary arGEN-X BV (arGEN-X) is a Pharmaceuticals and Healthcare company, based in the Netherlands. The company operates through Drug Discovery and manufacturing, Research and Development (R&D), and Biotechnology. ...